Why the study?
Do novel calcium antagonists that dilate efferent arterioles reduce proteinuria in patients with chronic renal disease?
Do novel calcium antagonists that dilate efferent arterioles reduce proteinuria in patients with chronic renal disease?
Novel calcium antagonists that dilate efferent arterioles, such as efonidipine, may provide better renal protection by reducing proteinuria in chronic renal disease compared to conventional agents.
No takes yet. Share an insight, caveat, or question.
May support BP-independent proteinuria reduction with novel calcium antagonists in CKD; leaves open need for randomized outcome trials.
Hayashi et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: